eClinical Technology and Industy News

Comanche Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for CBP-4888, an siRNA Investigational Therapy for the Treatment of Preeclampsia

Excerpt from the Press Release:

CONCORD, Mass., March 30, 2023 /PRNewswire/ — Comanche Biopharma Corp., a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for Comanche’s novel, siRNA therapy to treat preeclampsia. Preeclampsia is a prevalent hypertensive disorder of pregnancy for which there is no existing therapy that can modify disease progression.

“The FDA’s clearance of CBP-4888 allows us to take another major step toward developing a treatment for preeclampsia,” said Scott Johnson, M.D., Co-Founder and CEO of Comanche Biopharma. “We will now move expeditiously into a first-in-human clinical trial to evaluate this potential therapy.”

CBP-4888 is a subcutaneously delivered siRNA therapeutic that decreases the production of soluble fms-like tyrosine kinase-1 (sFLT1) in the placenta.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary EDC Platforms

Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?